Community Leukemia Clinical Research Drug Development
University of Colorado (CU) Cancer Center researchers have been on the leading edge of developing new therapies for leukemia. One of the most recent breakthrough therapies has been the development of venetoclax, a B-cell lymphoma-2 inhibitor, that that has shown profound results for adults with acute myeloid leukemia (AML) and has become a standard of care for patients with this disease all over the world.
Rachel Sauer | 
February 24, 2022
Cancer AstraZeneca Drug Development
AstraZeneca is pharmaceutical company committed to developing novel anti-cancer drugs. The University of Colorado Cancer Center is one of the fastest-growing academic cancer research centers in the United States, with hundreds of scientists and doctors working to better understand the disease. Recently, CU Cancer Center leaders visited the AstraZeneca Research and Development Campus in Gaithersburg, Maryland to discuss how a handshake between CU’s academia and AZ’s industry could help both take steps toward the ultimate goal: speeding the delivery of new drugs to cancer patients who need them.
Cancer Center | April 18, 2019
Cancer Health
March 20, 2023
An innovative cell squeezing technology showed great promise in a phase I trial against certain head and neck cancers.
Denver 7
March 16, 2023
Swati Patel, MD, MS, discusses younger people being diagnosed with colon cancer at nearly twice the rate than in 1995.
CPR
March 15, 2023
Doctors increasingly see people contracting colon cancer before the recommended screening age of 45.
KKTV
March 14, 2023
Colon cancer is one of the deadliest cancers -- but with early detection is also one of the most survivable. This is why regular screenings are so key.
